Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03064113 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease, COPD

Interventions

DRUG: Placebo
DRUG: TD-4208 700 μg
DRUG: TD-4208 350 μg
DRUG: Ipratropium 500 μg

Sponsor

Mylan Inc.

Collaborators

[object Object]